Healthcare industry

The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.

Organisers and more than 300 participants were very enthusiastic about the European BioFine life sciences congress recently held in Freiburg. Four different life sciences conferences were organised . Freiburg will also host BioFine 2009.

Dossier - 24/04/2008

Contract manufacture: the order books remain full

The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.

Boehringer Ingelheim enjoyed continued success in 2007 and its growth is outpacing the pharmaceuticals market for the eighth year in a row. The companys turnover rose by 8.8 in local currency to almost EUR 11 billion.

Vetter Pharma Fertigung GmbH Co has been granted approval by the American Food and Drug Administration FDA for the production of a new client drug. Vetter will now be filling injection systems with the new drug at its Ravensburg facility. Vetter has invested over 100 million euros.

The CEOs of pharmaceutical and life science companies are becoming increasingly aware that their companies are facing growing challenges and risks at the global level. At the same time they are also aware of more and more opportunities.

Nycomed and its licence holder Wyeth Pharmaceuticals a division of Wyeth NYSEWYE today announced the U.S. launch of an own generic version of PROTONIX Pantoprazole tablets in response to the at-risk launch of generic Pantoprazole tablets by Teva Pharmaceuticals USA Inc.

Micro-biolytics GmbH now based in the Esslingen-based Life Science Centre develops and produces microsystems solutions for bioanalytical issues. With the support of networks micro-biolytics is hoping to considerably expand its activities.

Only a few researchers combine different disciplines as effectively and with as much flair as Professor Dr.-Ing. Heinrich Planck director of the ITV Denkendorf. He combines mechanical textile and medical engineering both on the scientific and economic level at the same time as being a dedicated networker.